Ethambutol hydrochloride + Clarithromycin + Azithromycin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mycobacterium Avium-intracellulare Infection
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Trial Timeline
— → —
NCT ID
NCT00002140About Ethambutol hydrochloride + Clarithromycin + Azithromycin
Ethambutol hydrochloride + Clarithromycin + Azithromycin is a phase 3 stage product being developed by Pfizer for Mycobacterium Avium-intracellulare Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00002140. Target conditions include Mycobacterium Avium-intracellulare Infection, HIV Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002140 | Phase 3 | Completed |
Competing Products
20 competing products in Mycobacterium Avium-intracellulare Infection